HomeVideoSemaglutide and Cardiovascular Risks

Semaglutide and Cardiovascular Risks

The FDA requires manufacturers to assess the cardiovascular risk of all new therapies for type 2 diabetes. Semaglutide, a glucagon like peptide-1 analogue, lowers blood glucose, but does it increase cardiovascular risk? New research findings are summarized in a short video. Learn more at http://nej.md/1WoeHdF


Previous post
Suplemento Natural
Next post
Flavio Frisardi| Orofacial Pain Centre| Italy| Dentistry 2015 | Conference Series LLC

Leave a Reply

Be the First to Comment!

Notify of